Technology | Radiation Dose Management | April 04, 2019

Omega Medical Imaging Launches AI-enabled FluoroShield for Radiation Reduction

System combines AI, ultra-fast collimator and advanced image processing to reduce radiation exposure for interventional X-ray imaging

April 4, 2019 — The U.S. Food and Drug Administration (FDA) granted Omega Medical Imaging 510(k) clearance to offer their artificial intelligence (AI)-powered region of interest (ROI) radiation exposure reduction solution FluoroShield for interventional X-ray imaging on their flat panel detector CS-series product lines.

FluoroShield combines AI, an ultra-fast collimator and advanced image processing to deliver an ROI solution that has shown to reduce radiation exposure up to approximately 84 percent. The AI helps minimize X-ray dose to patients and staff while TruBlock technology completely blocks radiation. This delivers maximum radiation reduction while optimizing workflow, helping interventional clinicians better reach their ALARA (as low as reasonably achievable) goals.

For more information: www.omegamedicalimaging.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 07, 2020 | By Melinda Taschetta-Millane and Dave Fornell

COVID-19 Clinician Update

In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th

The agreement is intended to integrate Qure.ai’s proprietary technology for chest x-ray screening and head CT triage in the Nanox.Cloud to improve imaging solutions and increase patient access to medical imaging world-wide

News | Artificial Intelligence | April 07, 2020

Nanox Partners With Qure.ai to Integrate AI-based Algorithms for Medical Imaging

April 7, 2020 — -...

A recent study earlier this year in the journal Nature, which included researchers from Google Health London, demonstrated that artificial intelligence (AI) technology outperformed radiologists in diagnosing breast cancer on mammograms

Feature | Breast Imaging | April 06, 2020 | By Samir Parikh

Leveraging Artificial Intelligence to Enhance the Radiologist and Patient Experience

A recent study earlier this year in the journal Nature,

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor

Artificial Intelligence Greatly Speeds Radiation Therapy Treatment Planning

The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new

Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market.

Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market.

Feature | Radiation Dose Management | April 02, 2020 | By Melinda Taschetta-Millane

Drivers in Today’s Radiation Dose Management Market

Rising concerns over...

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron

Emerging Trends in Radiology

A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p